96851 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#2SYNTHETIC MULTIVALENT TUBERCULOSIS VACCINE
#3MYCOBACTERIUM T CELL EPITOPES, MEGAPOOLS AND USES THEREOF
#4METHOD FOR THE TREATMENT OF AN ACUTE RESPIRATORY DISTRESS SYNDROME
#5IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#6VACCINE CONSTRUCTS COMPRISING TUBERCULOSIS ANTIGENS
#7PEPTIDE COMPOSITION AND USES THEREOF
#8MYCOPLASMA HYOPNEUMONIAE SUBUNIT VACCINE AND PREPARATION METHOD AND USE THEREOF
#9IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF
#10ANTIBACTERIAL POLYPEPTIDES
#11IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#12IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#13MSP NANOPORES AND USES THEREOF
#14COMBINED VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS
#15SINGLE MOLECULE NANOPORE SEQUENCING METHOD
#16IMMUNOGENIC COMPOSITION FOR PARATUBERCULOSIS
#17METHODS FOR PRODUCING CMV VECTORS
#18Tuberculosis Antigen Cassettes
#19USE OF AMINO ACID SEQUENCES FROM MYCOBACTERIUM TUBERCULOSIS OR CORRESPONDING NUCLEIC ACIDS FOR DIAGNOSIS AND PREVENTION OF TUBERCULAR INFECTION, DIAGNOSTIC KIT AND VACCINE THEREFROM
#20PURIFICATION METHOD OF MYCOBACTERIUM-DERIVED NANOCARRIER PROTEIN
#21CONTROL OF SUBUNIT STOICHIOMETRY IN SINGLE-CHAIN MSP NANOPORES
#22MYCOBACTERIUM TUBERCULOSIS (Mtb) ADENOSINE TRIPHOSPHATE (ATP) SYNTHASE-EXPRESSING RECOMBINANT BACTERIUM, AND CONSTRUCTION METHOD AND EXPRESSION METHOD THEREOF
#23TUBERCULOSIS VACCINES
#24METHOD FOR THE TREATMENT OF ALLERGIC RHINITIS
#25BCG and IL-15 based molecules
#26IL-15-based molecules with anti-CD20 antibody and methods of use
#27MNEP MONOMER VARIANT AND APPLICATION THEREOF
#28METHOD FOR STIMULATING TUMOR-INFILTRATING LYMPHOCYTES WITH AN IL-15:IL-15R COMPLEX
#29IMPROVED CYTOSINE TO GUANINE BASE EDITORS
#30IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#31Compositions comprising IL-15N72D-based molecules and bacillus calmette-guerin (BCG)
#32ANALYTE SEQUENCING WITH NANOPORES
#33MSP nanopores and uses thereof
#34COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE SEQUENCING
#35Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis
#36IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF
#37Methods of treating a neoplasia with IL-15-based molecules and CTLA-4 antibody
#38MSP NANOPORES AND RELATED METHODS
#39Tuberculosis Compositions And Methods Of Using The Same
#40Vaccines and Antibodies for the Treatment and Prevention of Microbial Infections
#41METHOD
#42CS1 TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS
#43Method of detecting subspecies paratuberculosis infection
#44SCREENING SYSTEM FOR MYCOBACTERIUM TUBERCULOSIS INTEIN SPLICING INHIBITOR, CONSTRUCTION METHOD AND USE THEREOF
#45FLUORESCENT PROTEIN SENSOR CAPABLE OF QUANTITATIVELY MEASURING OXIDATION DEGREE OF METHIONINE RESIDUES OF SPECIFIC PROTEIN, AND USE THEREOF
#46Tuberculosis Compositions And Methods Of Treating Or Preventing Tuberculosis
#47LENTIVIRAL VECTORS ENABLING ROUTING ANTIGENS TO MHC-II PATHWAY AND INDUCING CD4+ AND CD8+ T-CELL RESPONSES IN A HOST
#48Kit and method for constructing long-acting depression animal model
#49Global gene regulators (GGR) as vaccine candidates against paratuberculosis
#50CAS9 PROTEINS INCLUDING LIGAND-DEPENDENT INTEINS
#51Tuberculosis antigen cassettes
#52METHOD FOR THE TREATMENT OF A RELAPSING-REMITTING CONDITION
#53IL-15-based molecules and methods of treating a neoplasia
#54Method of treating cancer with composition comprising IL-15-based molecules and BCG
#55Method for treating neoplasia with an anti-CD38 antibody and an IL-15:IL-15R complex
#56PEPTIDE FOR TREATING SEPSIS DERIVED FROM RV3364C PROTEIN OF MYCOBACTERIUM TUBERCULOSIS
#57IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES
#58Compositions comprising IL-15-based molecules and immune checkpoint inhibitor antibodies
#59CARRIER MATRIX COMPRISING DODECIN PROTEIN
#60M. TUBERCULOSIS AG85 PROTEINS AND METHODS OF USE
#61Protection from stress, anxiety, neuroinflammation, and cognitive dysfunction
#62CONSTRUCTION METHOD OF RECOMBINANT DRUG-RESISTANT MYCOBACTERIUM BOVIS BACILLUS CALMETTE-GUERIN (BCG) STRAIN AND PHARMACEUTICAL COMPOSITION FOR TREATING TUBERCULOSIS (TB)
#63IL-15-based molecules and methods of use thereof
#64Method for the treatment of a relapsing-remitting condition
#65HSP Fusion Protein with Anti-Chemorepellant Agent for Treatment of Cancer
#66METHODS FOR PRODUCTION OF ERGOTHIONEINE
#67MULTI-EPITOPIC CONSTRUCT
#68Msp nanopores and uses thereof
#69Analyte sequencing with nanopores
#70COMPOSITIONS AND METHODS OF DETERMINING A LEVEL OF INFECTION IN A SUBJECT
#71Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#72Attb cell line, transgenic cell lines derived therefrom, and methods of making the same
#73Method of detecting subspecies
#74Method for the Treatment of a Relapsing-Remitting Condition
#75Immunogenic compositions comprising polypeptides and fusions thereof
#76Recombinant cytomegalovirus vectors as vaccines for tuberculosis
#77NOVEL METHODS FOR INDUCING AN IMMUNE RESPONSE
#78Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
#79Tuberculosis compositions and methods of using the same
#80PEPTIDE COMPOSITION AND USES THEREOF
#81Compositions and methods for polynucleotide sequencing
#82Immunogenic composition for paratuberculosis
#83Protection from stress, anxiety, neuroinflammation, and cognitive dysfunction
#84PROTEIN-BASED MICELLES FOR THE DELIVERY OF HYDROPHOBIC ACTIVE COMPOUNDS
#85COMPOSITIONS AND METHODS FOR TREATING SECONDARY TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIUM INFECTIONS
#86Global gene regulators (GGR) as vaccine candidates against
#87Method for the treatment of a relapsing-remitting condition
#88RECONSTITUTION OF DNA-END REPAIR PATHWAY IN PROKARYOTES
#89IMMUNOGENIC PEPTIDES AND USE THEREOF
#90MSP nanopores and related methods
#91IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES
#92CS1 targeted chimeric antigen receptor-modified T cells
#93Methods of diagnosis and treatment of tuberculosis and infection
#94Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
#95NOVEL ADENOVIRUS
#96CAS9 proteins including ligand-dependent inteins
#97Msp nanopores and uses thereof
#98Immunogenic compositions comprising surface proteins and uses thereof
#99IL-15-based molecules and methods of use thereof
#100Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification
#101Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#102ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN
#103MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS
#104Tuberculosis antigen cassettes
#105Methods of Treating and Preventing Infections
#106Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
#107THERAPEUTIC COMPOSITION FOR INFLAMMATION/TISSUE INJURY
#108Fusion proteins comprising a Mtu ΔI-CM intein variant and methods of protein purification
#109Tuberculosis compositions and methods of treating or preventing tuberculosis
#110Global gene regulators (GGR) as vaccine candidates against paratuberculosis
#111Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
#112Combined vaccine against mycobacterium tuberculosis
#113Antigen-binding fusion proteins with modified HSP70 domains
#114Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
#115DIAGNOSTIC
#116Compositions and methods for polynucleotide sequencing
#117IL-15-based molecules and methods of use thereof
#118Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#119A MODIFIED PEPTIDE AS AN ANTICANCER AGENT
#120HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
#121HSP fusion protein with anti-chemorepellant agent for treatment of cancer
#122COMPOSITIONS AND METHODS OF DETERMINING A LEVEL OF INFECTION IN A SUBJECT
#123Expression of recombinant tetracycline efflux pumps for the production of lysine or lysine-derived products, and methods and applications thereof
#124Tuberculosis compositions and methods of using the same
#125Method for preventing or treating infection
#126CAS9 proteins including ligand-dependent inteins
#127Vaccines for prevention and treatment of tuberculosis
#128antigens
#129Composition for promoting maturation of dendritic cell containing fusion protein of Rv2299c and ESAT-6
#130Aldehyde tags, uses thereof in site-specific protein modification
#131Compositions and methods for the treatment or prevention of tuberculosis
#132Immunotherapies employing self-assembling vaccines
#133Genetically modified strains of
#134Methods and compositions to increase the rate of ligation reactions catalyzed by a sortase
#135MSP nanopores and related methods
#136Method for preventing or treating infection
#137specific peptides for detection of infection or immunization in non-human primates
#138Vaccines with interleukin-33 as an adjuvant
#139Compositions useful in the diagnostic of latently infected
#140MULTIPLEX HIGH-RESOLUTION DETECTION OF MICRO-ORGANISM STRAINS, RELATED KITS, DIAGNOSTICS METHODS AND SCREENING ASSAYS
#141Recombinant Mycobacterium Encoding A Heparin-Binding Hemagglutinin (HBHA) Fusion Protein And Uses Thereof
#142Multi-epitopic construct
#143Methods of treating and preventing influenza infections
#144Methods for inducing an immune response
#145Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#146NOVEL ADENOVIRUS
#147Immunogenic compositions against tuberculosis
#148Immunogenic compositions comprising polypeptides and fusions thereof
#149Remedy for bovine leukemia prophylaxis and use thereof
#150Expression of recombinant tetracycline efflux pumps for the production of lysine or lysine-derived products, and methods and applications thereof
#151Anti-Cancer DNA Vaccine Employing Plasmids Encoding Signal Sequence, Mutant Oncoprotein Antigen, and Heat Shock Protein
#152Tuberculosis vaccine compositions and related methods
#153Hetero-pores
#154Culture Medium for In-Vitro Cultivation of Mycobacterium Leprae (M. Leprae)
#155Recombinant cytomegalovirus vectors as vaccines for tuberculosis
#156Tuberculosis compositions and methods of treating or preventing tuberculosis
#157CS1 targeted chimeric antigen receptor-modified T cells
#158Mutant pores
#159HPV-related fusion protein and applications thereof
#160METHODS OF DIAGNOSIS AND TREATMENT OF TUBERCULOSIS AND INFECTION
#161Mutant pores
#162PEPTIDE COMPOSITION AND USES THEREOF
#163Global gene regulators (GGR) as vaccine candidates against
#164Mycobacterium Antigens
#165Compositions and methods for polynucleotide sequencing
#166CAS9 proteins including ligand-dependent inteins
#167Antigen-Binding Fusion Proteins with Modified HSP70 Domains
#168Multivalent vaccine for protection against mycobacterial infections and methods of using the same
#169Compositions useful in the diagnostic of latently infected
#170proteins
#171Analyte sequencing with nanopores
#172Method for preventing or treating infection
#173Composite antigenic sequences and vaccines
#174Prevention and treatment of mycobacterium infection
#175METHODS AND COMPOSITIONS FOR SITE-SPECIFIC LABELING OF PEPTIDES AND PROTEINS
#176Aldehyde tags, uses thereof in site-specific protein modification
#177Methods for producing microcompartments
#178Recombinant BCG expressing antigens of the ESX-1 secretion system
#179Diagnostic reagents
#180Compositions and methods
#181Method for preventing or treating infection
#182Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
#183MUTANT PORES
#184Proteins expressed by and not by BCG and their use as diagnostic reagents and vaccines
#185M.tuberculosis vaccines
#186MSP nanopores and uses thereof
#187Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of
#188Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance
#189Polymer particles and uses thereof
#190Immunogenic compositions and methods
#191Vaccine and therapeutic delivery system
#192Fusion of heterooligomeric mycobacterial antigens
#193Immunity enhancing therapeutic vaccine for HPV and related diseases
#194specific peptides for detection of infection or immunization in non-human primates
#195Mycobacterial antigen composition
#196Vaccines with interleukin-33 as an adjuvant
#197A SINGLE OR MULTISTAGE MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS SUBUNIT VACCINE
#198COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS
#199Biomarkers for (MAP)
#200Compositions and methods for the treatment or prevention of tuberculosis
#201Efficient mucosal vaccination mediated by the neonatal Fc receptor
#202Compositions and methods
#203Recombinant as a vaccine
#204Proteins expressed by and not by BCG and their use as diagnostic reagents and vaccines
#205Mycobacterium antigens
#206Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
#207MSP nanopores and related methods
#208Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
#209Engineered intein for improved production of protein-intein fusions
#210Vaccine and therapeutic delivery system
#211Prevention and treatment of mycobacterium infection
#212BIOLOGICAL MATERIALS AND USES THEREOF
#213Compositions and methods to prevent cancer with cupredoxins
#214Use of amino acid sequences from or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#215Primers, probes, and methods for mycobacterium tuberculosis specific diagnosis
#216Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof
#217vaccines
#218Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
#219Immunoglobulin-binding human mycoplasma antigens and methods of use thereof
#220Method for preventing or treating infection
#221PLASTID-EXPRESSED MYCOBACTERIUM TUBERCULOSIS VACCINE ANTIGENS ESAT-6 AND MTB72F FUSED TO CHOLERA TOXIN B SUBUNIT
#222Mycobacterial antigen vaccine
#223METHOD FOR ATTENUATING A BACTERIUM OF THE MYCOBACTERIUM TUBERCULOSIS COMPLEX FOR PRODUCING A TUBERCULOSIS VACCINE
#224Compositions and methods for polynucleotide sequencing
#225DIAGNOSTIC REAGENTS
#226Modified antigens
#227Tuberculosis TB vaccine to prevent reactivation
#228Aldehyde tags, uses thereof in site-specific protein modification
#229Enhancing immunity to tuberculosis
#230Live recombinant booster vaccine against tuberculosis
#231Immunogenic compositions and methods
#232Tuberculosis compositions and methods of using the same
#233Immunotherapy targeting intracellular pathogens
#234METHOD OF DETECTING ACTIVE TB
#235ENGINEERING PLANTS FOR EFFICIENT UPTAKE AND UTILIZATION OF UREA TO IMPROVE CROP PRODUCTION
#236Peptides from chaperonin 60.1
#237Compositions and methods
#238MSP nanopores and related methods
#239Msp nanopores and related methods
#240porins and toxins and related methods
#241Mycobacterium antigens
#242Global gene regulators (GGR) as vaccine candidates against paratuberculosis
#243USE OF MYCOBACTERIUM AVIUM PARATUBERCULOSIS PEPTIDES TO DIAGNOSE TYPE 1 DIABETES
#244Msp nanopores and related methods
#245Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
#246Mutant pores
#247Compositions and methods
#248Exosomes and diagnostic biomarkers
#249Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
#250Assay method for peptide specific T-cells
#251Small molecule-dependent inteins and uses thereof
#252Anticancer agent
#253Method for preventing or treating infection
#254ANTIVIRAL COMPOSITION
#255Antigens and epitopes derived from
#256Recombinant mycobacterium as a vaccine
#257Tuberculosis diagnostic test
#258Modified prokaryotic ubiquitin-like protein and methods of use thereof
#259Use of amino acid sequences from mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom
#260Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
#261Recombinant microorganisms and uses thereof
#262Immunogenic compositions comprising polypeptides and fusions thereof
#263Immunogenic compositions against tuberculosis
#264Composite antigenic sequences and vaccines
#265THERAPEUTIC TB VACCINE
#266Analyte sequencing with nanopores
#267Methods for detecting a infection
#268Vaccine and therapeutic delivery system
#269COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS
#270METHOD FOR THE PURIFICATION OF HBHA
#271MYCOBACTERIA-DERIVED DNA MISMATCH REPAIR NUCLEOTIDE SEQUENCES AND USES THEREOF
#272Compositions and methods to prevent cancer with cupredoxins
#273Modified tuberculosis antigens
#274Mycobacterial vaccines
#275Vaccine for Modulating Between T1 and T2 Immune Responses
#276Vaccine for modulating between T1 and T2 immune responses
#277Tuberculosis diagnostic test
#278Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
#279Mycobacterium tuberculosis fusion protein and uses thereof
#280Bacterial ATP synthase binding domain
#281Efficient mucosal vaccination mediated by the neonatal Fc receptor
#282Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of BCG and
#283COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
#284Mycobacterial mutants inducing IL-12
#285Mesothelin antibody protein fusions and methods of use
#286Bioassay and peptides for use therein
#287Tuberculosis vaccines comprising antigens expressed during the latent infection phase
#288Methods for producing an immune response to tuberculosis
#289Proteins expressed by and not by BCG and their use as diagnostic reagents and vaccines
#290Compositions and Methods for Determining Immune Status
#291Mycobacterial antigens expressed under low oxygen tension
#292MSP nanopores and related methods
#293Tuberculosis TB vaccine to prevent reactivation
#294Mycobacterial antigens expressed during latency
#295Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same
#296Tuberculosis vaccine with improved efficacy
#297Methods for detecting a infection
#298IMMUNOTHERAPY TARGETING INTRACELLULAR PATHOGENS
#299TUBERCULOSIS ANTIGENS, IMMUNOGENIC COMPOSITIONS, DIAGNOSTICS AND METHODS RELATED TO THE SAME
#300Synthetic antigenic peptides and lipopeptides derived from subsp.